Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE: MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country. Countries are negotiating prices with Merck and Pfizer Inc (NYSE: PFE).

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

Intel

Buying yield can be a healthy strategy, but when it comes to three Dow stocks dogged-looking price charts may quickly trump income generation. The post 3 Dow Stocks To Avoid appeared first on InvestorPlace.

3 Dow Stocks To Avoid

Let's see if Merck & Co. (MRK) stock is a good choice for value-oriented investors right now from multiple angles.

Is Merck & Co. (MRK) Suitable for Value Investors Now?

Andersons

Mr. Cooper Group Inc

Chevron

Navient

Safe Bulkers

These seven top value stocks could outperform in the coming years, especially against the backdrop of multiple federal interest hikes. The post 7 Value Stocks Primed to Take Off in a Rising Rate Environment appeared first on InvestorPlace.

7 Value Stocks Primed to Take Off in a Rising Rate Environment

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications. Under the agreement terms, Curve will receive an upfront payment and be eligible to receive research, development, and commercial milestones totaling up to $1.7 billion should all five therapeutic programs succeed.

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Organon & Co

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Acquires Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong, Macau, Agrees to Acquire these Products in Vietnam

Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People's Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces New Leadership for Human Health Business

Merck Announces New Leadership for Human Health Business

Blackrock Inc

Bank of Nova Scotia

Cummins

Lowe's

Novartis

PPG Industries

Stanley Black & Decker

V.F.

The 2022 correction is frustrating many investors who have been spoiled by years of Buffett-like returns with almost no volatility.

9 No-Brainer Dividend Blue-Chips For A Rich Retirement

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA + Abiraterone Reduced Risk of Disease Progression or Death by 34% vs Abiraterone in 1L Metastatic Castration-Resistant Prostate Cancer

LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status

Johnson & Johnson

Coca-Cola

McDonald's

If there's one thing recent macroeconomic and stock market turbulence should reteach us, it's that the best blue-chip dividend stocks never go out of style. And the Dow's best dividend stocks are proving that handily so far in 2022.

5 Best Dow Dividend Stocks to Buy Now

Abbott Labs

Amgen

Baxter

Cerner

Quest Diagnostics

Eli Lilly

Pfizer

Stryker

UnitedHealth Group

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Event to Discuss Long-Term Environmental, Social and Governance Priorities

Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities

Merck is 90% focused on human drugs and is highly diversified globally. On November 22nd, Merck completed the $11.7 billion Acceleron acquisition.

Buy Merck Today To Retire Rich Tomorrow

Merck has demonstrated strong growth and maintains very healthy margins. It also has a robust pipeline, which combined with its existing portfolio, gives it runway for continued growth.

Merck: Your Opportunity Is Knocking

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Pivotal Phase 3 Data for KEYTRUDA in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

Bristol-Myers

Regeneron Pharmaceuticals

Should investors be putting these pharmaceutical stocks on their watchlists?

4 Pharmaceutical Stocks To Watch In February 2022￼

Merck & Co. MRK, -1.25% and partner privately held Ridgeback Biotherapeutics said Tuesday they have completed manufacturing of 10 million doses of their COVID antiviral molnupiravir and are on track to make at least 20 million courses in 2022. The pair have supplied 3.1 million course to the U.S. government for use in the U.S., they said in a joint statement.

Merck and Ridgeback Biotherapeutics on track to make 20 million courses of COVID antiviral in 2022

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Supplied to the U.S. Government

Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

Merck persisted in developing an oral antiviral medication thought to be a game changer -- until it wasn't.

Will a New FDA-Approved COVID Pill Propel This Healthcare Company's Stock?

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Guggenheim Oncology Conference 2022

Merck to Participate in the Guggenheim Oncology Conference 2022

Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M

Merck & Co., Inc. (MRK) CEO Rob Davis on Q4 2021 Results - Earnings Call Transcript

Merck & Co Inc (NYSE: MRK) on Thursday said its Q4 profit and revenue topped Wall Street estimates. Shares still fell nearly 2.0% on slightly weaker-than-expected guidance for full-year earnings.

Merck CEO on Q4 results: ‘all of our growth drivers are delivering'

Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Merck Stock (MRK)